<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01443221</url>
  </required_header>
  <id_info>
    <org_study_id>CWP-KAD-05</org_study_id>
    <nct_id>NCT01443221</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Mitiglinide and Metformin in Free Combination and Fixed-dose Combination in Healthy Male Subjects.</brief_title>
  <official_title>Open-label, Randomized, Single-dose, 2-way Crossover Study to Investigate Safety and Pharmacokinetics of Mitiglinide and Metformin in Free Combination and Fixed-dose Combination in Healthy Male Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate safety and pharmacokinetics of mitiglinide and metformin in a fixed-dose
      combination of mitiglinide/metformin, compared with free combination of mitiglinide and
      metformin in healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Korean clinical practice guidelines on DM recommend that a second oral agent with a
      different mechanism of action be combined to the regimen when adequate glycemic control is
      difficult to achieve with an oral hypoglycemic agent accompanied dietary therapy. Therefore,
      a concurrent administration of metformin, a inhibitor of gluconeogenesis, and mitiglinide, an
      insulin secretagogue, could be an effective and ideal regimen for management of diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the pharmacokinetic profiles(Cmax, AUClast) of fixed-dose combination versus free dose combination in healthy volunteers</measure>
    <time_frame>Up to 36 hours postdose for each period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the pharmacokinetic profiles(tmax, t1/2, AUC0-âˆž) of fixed-dose combination versus free dose combination in healthy volunteers</measure>
    <time_frame>Up to 36hours postdose for each period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Free combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Free combination of Mitiglinide 10mg and Metformin 500mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed-dose combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitiglinide and metformin</intervention_name>
    <description>Free combination of Mitiglinide 10mg and Metformin 500mg</description>
    <arm_group_label>Free combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitiglinide and metformin</intervention_name>
    <description>Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg</description>
    <arm_group_label>Fixed-dose combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males

          -  Subject with adequate clinical laboratory test results (hematology, blood chemistry,
             serology, drug abuse, urinalysis etc.)

          -  Subject with normal results in blood pressure, pulse, body temperature and ECG test

          -  Subject with body mass index (BMI) between 18.5 kg/m2 and to 25 kg/m2

        Exclusion Criteria:

          -  Clinically significant functional disorder or acute disease

          -  Chronic disease affecting the absorption, metabolism or excretion of drug

          -  Any study drug administration within 90 days before the first drug administration

          -  Use of medicine affecting drug metabolism (inhibition, induction) such as barbital,
             within 30 days before the first drug administration
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wooseong Hur, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2011</study_first_submitted>
  <study_first_submitted_qc>September 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2011</study_first_posted>
  <last_update_submitted>September 28, 2011</last_update_submitted>
  <last_update_submitted_qc>September 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mitiglinide</keyword>
  <keyword>metformin</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitiglinide</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

